Week in Review: 3SBio Uses M&A to Expand Portfolio of Biosimilars

Shenyang's 3SBio expanded its biosimilar business by acquiring 47% of Shanghai CP Guojian Pharma for $213 million, bringing its stake to 54%; Eisai of Japan entered China's generic drug sector by paying $78 million for Liaoning TianYi Biological Pharma; a Sinopharm affiliate signed a $50 million deal for China rights to an oral insulin product developed by Jerusalem's Oramed Pharma; Hangzhou Tigermed paid $28 million to acquire DreamCIS, a Korean clinical-stage CRO; Ascletis of Hangzhou raised $20 million from Goldman Sachs in preparation for an IPO; Shanghai's Frontline BioVentures led a Series A funding for Sino Health, a Sinopharm investment vehicle; Shuwen Biotech of Hangzhou partnered with Germany's BioNTech Diagnostics to commercialize BioNTech’s molecular breast cancer test in China; Meinian Onehealth Healthcare made a bid to take iKang Healthcare private, topping management's offer by 24%; and TaiGen Biotech of Taiwan said the IV formulation of Taigexyn®, the company's novel antibiotic for drug-resistant infections, posted positive results in a Taiwan-China clinical trial. More details.... Stock Symbols: (HK: 1530) (TO: 4523) (NSDQ: ORMP) (SHZ: 300347) (NSDQ: KANG) (TWO: 4157) Share this with colleagues: // //